27 completed, 5 terminated, 5 unknown, 2 active not recruiting. 21 Phase 2, 21 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 16, Not yet recruiting 2, Terminated 2, Recruiting 1 |
| Phase 3 | 21 | Completed 11, Unknown 5, Terminated 3, Active not recruiting 2 |
| Phase 1 | 1 | Completed 1 |
Follow Lymphoma Study Association: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 95 | 2026-12-01 | 2026-09-14 |
| Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse golcadomide - Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Recruiting | The Lymphoma Academic Research Organisation | 65 | 2024-06-14 | 2026-06-04 |
| Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 Mosunetuzumab, Lenalidomide, Rituximab - Follicular Lymphoma | Phase 3 | Active not recruiting | The Lymphoma Academic Research Organisation | 790 | 2024-06-07 | 2026-09-25 |
| Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma Tislelizumab - Classical Hodgkin Lymphoma | Phase 2 | Completed | BeiGene | 46 | 2020-08-20 | 2025-09-24 |
| Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients Nivolumab, Rituximab, Gemcitabine - Lymphoma, Non-Hodgkin | Phase 2 / Phase 3 | Completed | Universität des Saarlandes | 348 | 2017-12-05 | 2025-01-28 |
| International Extranodal NK/T-cell Lymphoma Project Extranodal NK/T-cell Lymphoma, Nasal Type | Completed | Samsung Medical Center | 770 | 2013-01-01 | 2017-04-11 | |
| Study of Mantle Cell Lymphoma Treatment by RiBVD RiBVD - Mantle Cell Lymphoma | Phase 2 | Completed | French Innovative Leukemia Organisation | 76 | 2011-10-01 | 2016-03-16 |
| Lenalidomide and R-CHOP in B-cell Lymphoma Lenalidomide and R-CHOP - Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Lymphoma Study Association | 108 | 2009-01-06 | 2018-08-23 |
| Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Rituximab, Watch and wait - Mantle Cell Lymphoma | Phase 3 | Completed | French Innovative Leukemia Organisation | 299 | 2008-09-01 | 2018-04-27 |
| Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma Lymphoma, Follicular | Completed | Lymphoma Study Association | 121 | 2007-09-18 | 2018-08-23 | |
| Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan), ASCT, Rituximab - Lymphoma, Large Cell, Diffuse | Phase 2 | Completed | Lymphoma Study Association | 75 | 2007-08-01 | 2018-03-07 |
| Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis Rituximab, Cytarabine - Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 60 | 2007-07-01 | 2018-08-23 |
| Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma ZARNESTRA (Tipifarnib) - Mantle Cell Lymphoma | Phase 2 | Terminated | Lymphoma Study Association | 11 | 2007-06-01 | 2018-08-23 |
| Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma ABVD q4 weeks, BEACOPP escalated q3 weeks, IN-RT 30 Gy (+ boost 6 Gy residual) - Lymphoma | Phase 3 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 1952 | 2006-10-01 | 2021-02-03 |
| Mini-CHOP and Rituximab in Patients Aged Over 80 Years R mini CHOP - Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 150 | 2006-04-01 | 2019-08-26 |
| Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma Velcade, Doxorubicin, Prednisone - Peripheral T-cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 60 | 2006-01-08 | 2018-08-23 |
| A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma Rituximab, Prednisone, Doxorubicine - Untreated T-cell Angioimmunoblastic Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 27 | 2005-12-01 | 2017-03-13 |
| A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma Bortezomib - Follicular Lymphoma | Phase 2 | Terminated | Lymphoma Study Association | 87 | 2005-09-01 | 2010-10-26 |
| Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma Zevalin plus BEAM - B-Cell Lymphoma | Phase 2 | Completed | Lymphoma Study Association | 75 | 2005-03-01 | 2006-09-08 |
Showing 20 of 42. Sign in to see all of them.
Lymphoma (15) · Lymphoma, Large B-Cell, Diffuse (15) · Lymphoma, Follicular (8) · Lymphoma, Mantle-Cell (8) · Hodgkin Disease (4) · Lymphoma, B-Cell (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Non-Hodgkin (3) · Recurrence (3) · Waldenstrom Macroglobulinemia (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large-Cell, Immunoblastic (1)
Rituximab (19) · Cyclophosphamide (11) · Doxorubicin (10) · Prednisone (8) · Vincristine (6) · Cytarabine (5) · Etoposide (5) · Bleomycin (4) · Carmustine (4) · Melphalan (4) · fludarabine (4) · Bortezomib (3) · Dexamethasone (3) · Interferon-alpha (3) · ABVD protocol (2)
France (35) · Belgium (20) · Switzerland (8) · Netherlands (6) · Germany (5) · Poland (5) · Australia (4) · Italy (4) · Spain (4) · Czechia (3) · Portugal (3) · United Kingdom (3) · Austria (2) · Denmark (2) · Israel (2)
Corinne Haioun, MD (7) · Bertrand Coiffier, MD (4) · Christian Gisselbrecht, MD (3) · Gilles A Salles, MD PhD (2) · H. Eghbali, MD (2) · Achiel Van Hoof, MD (1) · Alain Delmer, MD (1) · Alessandro Levis, MD (1) · Anna Sureda (1) · Bengt Glimelius, MD (1) · Bertrand Joly, MD (1)
PMID 26373676, PMID 27282998, PMID 20032498, PMID 24687837, PMID 10586336, PMID 18077791, PMID 18799723, PMID 20660832, PMID 21176949, PMID 21482186, PMID 21546499, PMID 22118442, PMID 22873532, PMID 22885164, PMID 23065509, PMID 23091101, PMID 23109699, PMID 23233721, PMID 23578722, PMID 23753028, PMID 24637998, PMID 25029908, PMID 25072780, PMID 25385729, PMID 26022239, PMID 27114593, PMID 27313086, PMID 28327893, PMID 28601705, PMID 28953447, PMID 29229324, PMID 29437590, PMID 31339826, PMID 31804876, PMID 35737565, PMID 36469833, PMID 36541117, PMID 37992261, PMID 38669626, PMID 39774828, PMID 40135712, PMID 42848781
2025 (2), 2004 (1), 2005 (1), 2019 (1)